Multifactorial approach to predicting resistance to anthracyclines

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1578-1586

  Desmedt, Christine ^{a,b,c,d,e,f,g,h,i,j,k}   Di Leo, Angelo ^{a,b,c,d,e,f,g,h,i,j,k}   De Azambuja, Evandro ^{a,b,c,d,e,f,g,h,i,j,k}   Larsimont, Denis ^{a,b,c,d,e,f,g,h,i,j,k}   Haibe Kains, Benjamin ^{a,b,c,d,e,f,g,h,i,j,k}   Selleslags, Jean ^{a,b,c,d,e,f,g,h,i,j,k}   Delaloge, Suzette ^{a,b,c,d,e,f,g,h,i,j,k}   Duhem, Caroline ^{a,b,c,d,e,f,g,h,i,j,k}   Kains, Jean Pierre ^{a,b,c,d,e,f,g,h,i,j,k}   Carly, Birgit ^{a,b,c,d,e,f,g,h,i,j,k}   Maerevoet, Marie ^{a,b,c,d,e,f,g,h,i,j,k}   Vindevoghel, Anita ^{a,b,c,d,e,f,g,h,i,j,k}   Rouas, Ghislane ^{a,b,c,d,e,f,g,h,i,j,k}   Lallemand, Françoise ^{a,b,c,d,e,f,g,h,i,j,k}   Durbecq, Virginie ^{a,b,c,d,e,f,g,h,i,j,k}   Cardoso, Fatima ^{a,b,c,d,e,f,g,h,i,j,k}   Salgado, Roberto ^{a,b,c,d,e,f,g,h,i,j,k}   Rovere, Rodrigo ^{a,b,c,d,e,f,g,h,i,j,k}   Bontempi, Gianluca ^{a,b,c,d,e,f,g,h,i,j,k}   Michiels, Stefan ^{a,b,c,d,e,f,g,h,i,j,k}   Buyse, Marc ^{a,b,c,d,e,f,g,h,i,j,k}   Nogaret, Jean Marie ^{a,b,c,d,e,f,g,h,i,j,k}   Qi, Yuan ^{a,b,c,d,e,f,g,h,i,j,k}   Symmans, Fraser ^{a,b,c,d,e,f,g,h,i,j,k}   Pusztai, Lajos ^{a,b,c,d,e,f,g,h,i,j,k}   D'Hondt, Véronique ^{a,b,c,d,e,f,g,h,i,j,k}   Piccart Gebhart, Martine ^{a,b,c,d,e,f,g,h,i,j,k}   Sotiriou, Christos ^{a,b,c,d,e,f,g,h,i,j,k}   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c IRIS   (Belgium)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e Clinique Saint Pierre of Ottignies   (Belgium)

^f Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^g INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^h Hospital of Prato   (Italy)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^k UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 79955008762     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.2231     Document Type: Article

References (32)

1. Slamon DJ, Press MF: Alterations in the TOP2A and HER2 genes: Association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 101:615-618, 2009
2. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005 (Pubitemid 46291811)
3. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER- 2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24:2428-2436, 2006 (Pubitemid 46630618)
4. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002 (Pubitemid 34517647)
5. Park K, Kim J, Lim S, et al: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631-634, 2003 (Pubitemid 36287375)
6. Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211, 2004 (Pubitemid 38077022)
7. Arriola E, Moreno A, Varela M, et al: Predictive value of HER-2 and topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur J Cancer 42:2954-2960, 2006 (Pubitemid 44667470)
8. Bartlett JM, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027-5235, 2008
9. O'Malley FP, Chia S, Tu D, et al: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650, 2009
10. MacGrogan G, Rudolph P, Mascarel Id I, et al: DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 89:666-671, 2003 (Pubitemid 37076170)
11. Tinari N, Lattanzio R, Natoli C, et al: Changes of topoisomerase IIalpha expression in breast tumours after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 12:1501-1506, 2006
12. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al: Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181-189, 2007 (Pubitemid 350045015)
13. Di Leo A, Isola J, Piette F, et al: A metaanalysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracyclines-based adjuvant therapy. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 705)
14. Bonnefoi H, Potti A, Delorenzi M, et al: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: A substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071-1078, 2007 (Pubitemid 350182953)
15. Durbecq V, Di Leo A, Cardoso F, et al: Comparison of topoisomerase- IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 77:199-204, 2003 (Pubitemid 36197634)
16. Di Leo A, Larsimont D, Gancberg D, et al: HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081-1089, 2001 (Pubitemid 32834488)
17. Pawitan Y, Bjöhle J, Amler L, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res 7:953-964, 2005
18. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246, 2007 (Pubitemid 46640570)
19. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
20. Marchio C, Natrajan R, Shiu KK, et al: The genomic profile of HER2-amplified breast cancers: The influence of ER status. J Pathol 216:399-407, 2008
21. Denkert C, Loibl S, Noske A, et al: Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
22. Farmer P, Bonnefoi H, Anderle P, et al: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15:68-74, 2009
23. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998 (Pubitemid 28363030)
24. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998 (Pubitemid 28041584)
25. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003 (Pubitemid 46606344)
26. Zitvogel L, Apetoh L, Ghiringhelli F, et al: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 18:1991- 2001, 2008 (Pubitemid 351872317)
27. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
28. Pal SK, Childs BH, Pegram M: Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res Treat 119:25-32, 2010
29. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
30. Slamon DJ, Mackey J, Robert N, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 13)
31. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 3 T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC 3 TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 62)
32. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008 (Pubitemid 351767337)